Metagen Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Metagen Therapeutics - overview
Established
2020
Location
Tsuruoka-shi, Yamagata, Japan
Primary Industry
Biotechnology
About
Founded in 2020 and based in Yamanashi, Japan, Metagen Therapeutics, Inc. , d. b. a.
Metagen Therapeutics, is a pharmaceutical company that engages in the research and development of new drugs and medical treatments using microbiome science. In February 2026, Metagen Therapeutics, Inc. raised JPY 1. 19 billion in series B from Nippon Venture Capital, MIRAIDOOR, Global Brain, Fujita Innovation Capital, Tokai Tokyo Investment, Green Coinvest, MatsukiyoCocokara & Co.
, and Medipal Holdings Co. , Ltd. As of February 2026, the company plans to advance microbiome drug research, expand clinical development, strengthen data platforms, hire talent, and prepare for regulatory and commercialization activities.
Current Investors
Fast Track Initiative, Keio Innovation Initiative, JAFCO Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics, Healthcare, Oncology/Cancer Treatment, Medical Devices & Equipment, Pharmaceutical Research & Development
Website
www.metagentx.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.